Understanding Mutations in the RAS Family of Genes
Mutations in the RAS family of genes (KRAS, NRAS, HRAS) commonly occur in cancers and represent one of the most common driver mutations in cancers. As such, considerable efforts have been made to target these mutant genes to advance new therapeutic strategies to combat cancers.
It is thought that 30% of all cancer deaths are related to RAS mutations. These occur most commonly in solid tumors such as lung cancer, gastrointestinal cancers, malignant melanoma and various leukemias and myelomas. Amongst gastrointestinal cancers, the vast majority of pancreatic cancers harbor KRAS mutations, and many colorectal cancers harbor KRAS mutations.
Moffitt has therefore a strong interest in developing new therapies that can help patients with RAS mutations. RAS mutations are commonly assessed using next-generation DNA sequencing panels, either using tumor material or blood-based assays. Within each type of RAS gene, there can be specific mutations that require specific therapies. For example, KRAS G12C mutations are common in lung cancer and can be targeted with existing FDA-approved compounds such as adagrasib and sotorasib. However, more agents are under development that can target each gene and individual mutations.
Aided by our Precision Medicine team and our extensive clinical trial portfolio, we have increased the opportunities for patients to receive new and promising agents that target RAS mutations and have multiple additional RAS clinical trials in the pipeline that will be opening to accrual soon.
RAS Mutation Trials Currently Open:
- MCC 22007: First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
- MCC 22002: A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
- MCC 22685: Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
- MCC 21626: A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
- MCC 21518: A Phase 1/1b Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation Positive Solid Tumors
To inquire more about clinical trials for RAS mutations or refer a patient with cancer or a suspicious tumor finding, please complete our online form or contact a physician liaison for assistance. As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.